title: High-dose chemotherapy containing busulfan followed by bone marrow transplantation in 24 children with refractory or relapsed non-Hodgkin's lymphoma.
abstract: Twenty-four children with relapsed or refractory non-Hodgkin's lymphoma underwent high-dose chemotherapy (HDC) with bone marrow transplantation (BMT). HDC comprised in all cases busulfan (16 mg/kg or 600 mg/m2), with either cyclophosphamide (200 mg/kg or 4.4 g/m2) and/or melphalan (140 mg/m2). Twenty-three of these children had received second-line therapy before receiving HDC. There were 16 B cell and eight T cell lymphomas. Twenty-three patients were evaluable at day 30 post-BMT; 19 were in complete remission, four did not respond. Eight patients are long-term survivors between 62 and 296 weeks after BMT. Among the seven children with resistant disease before HDC, only one is a long-term survivor. No toxic deaths occurred. The main adverse side effect was hepatic veno-occlusive disease which occurred in four patients, but resolved completely in all cases. Comparisons with other classic HDC regimens in relapsed childhood lymphomas show that HDC containing busulfan with BMT appears reasonably safe and is effective in refractory or relapsed lymphomas, even in these highly previously treated patients.
authors.affiliation: Pediatric Department, Institut Gustave Roussy, Villejuif, France.
authors.forename: H A
authors.initials: HA
authors.lastname: Loiseau
authors.forename: O
authors.initials: O
authors.lastname: Hartmann
authors.forename: D
authors.initials: D
authors.lastname: Valteau
authors.forename: H
authors.initials: H
authors.lastname: McDowell
authors.forename: L
authors.initials: L
authors.lastname: Brugières
authors.forename: G
authors.initials: G
authors.lastname: Vassal
authors.forename: C
authors.initials: C
authors.lastname: Kalifa
authors.forename: C
authors.initials: C
authors.lastname: Patte
authors.forename: J
authors.initials: J
authors.lastname: Lemerle
mesh_terms: D000293:Adolescent; D002066:Busulfan / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000009:adverse effects / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D005260:Female; D006504:Hepatic Veno-Occlusive Disease / Q000139:chemically induced / Q000453:epidemiology; D006801:Humans; D015994:Incidence; D016393:Lymphoma, B-Cell / Q000188:drug therapy / Q000601:surgery*; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000601:surgery*; D016399:Lymphoma, T-Cell / Q000188:drug therapy* / Q000601:surgery*; D008297:Male; D008558:Melphalan / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D003520:Cyclophosphamide; D002066:Busulfan; D008558:Melphalan